Trading

Bayer shares up after first trial win over Roundup

Published by maria gbaf

Posted on October 6, 2021

1 min read

· Last updated: January 31, 2026

Add as preferred source on Google
Lawmaker Kim Leadbeater discusses UK's assisted dying law changes - Global Banking & Finance Review
Image of Kim Leadbeater addressing the media about proposed changes to the UK's assisted dying law, emphasizing the removal of High Court judge sign-off to enhance the legislative process.

Bayer's Stock Rises Following Roundup Trial Victory

BERLIN (Reuters) – Shares in Bayer AG rose 2.5% in pre-market trade on Wednesday after the German agricultural and pharmaceuticals firm won its first trial over claims its Roundup weedkiller causes cancer.

A California jury found that the herbicide was not a substantial cause of a child’s rare form of non-Hodgkin’s lymphoma, the company said on Tuesday. The verdict is the fourth involving Roundup and the first in the company’s favor.

Roundup-related lawsuits have dogged Bayer since it acquired the brand as part of its $63 billion purchase of agricultural seeds and pesticides maker Monsanto in 2018.

(Reporting by Emma Thomasson; Editing by Muralikumar Anantharaman)

Key Takeaways

  • Bayer shares rose 2.5% in pre-market trading.
  • A California jury ruled in favor of Bayer in a Roundup trial.
  • The trial involved claims of Roundup causing cancer.
  • This is Bayer's first legal win over Roundup-related lawsuits.
  • Bayer acquired Roundup in its $63 billion Monsanto purchase.

Frequently Asked Questions

What is the main topic?
The article discusses Bayer's share increase following a legal victory in a Roundup cancer trial.
What was the trial about?
The trial was about claims that Bayer's Roundup weedkiller causes cancer.
What was the outcome of the trial?
A California jury ruled that Roundup was not a substantial cause of a child's cancer.

Related Articles

More from Trading

Explore more articles in the Trading category